NO20011891L - Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon - Google Patents

Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon

Info

Publication number
NO20011891L
NO20011891L NO20011891A NO20011891A NO20011891L NO 20011891 L NO20011891 L NO 20011891L NO 20011891 A NO20011891 A NO 20011891A NO 20011891 A NO20011891 A NO 20011891A NO 20011891 L NO20011891 L NO 20011891L
Authority
NO
Norway
Prior art keywords
beta
inhibitors
screening
amyloid
radioligands
Prior art date
Application number
NO20011891A
Other languages
English (en)
Norwegian (no)
Other versions
NO20011891D0 (no
Inventor
Robert C Zaczek
Richard Eric Olson
Dietmar A Seiffert
Lorin Andrew Thompson
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of NO20011891D0 publication Critical patent/NO20011891D0/no
Publication of NO20011891L publication Critical patent/NO20011891L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
NO20011891A 1998-11-12 2001-04-17 Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon NO20011891L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10814798P 1998-11-12 1998-11-12
US13128499P 1999-04-27 1999-04-27
PCT/US1999/026715 WO2000028331A1 (en) 1998-11-12 1999-11-12 Use of radioligands to screen inhibitors of amyloid-beta peptide production

Publications (2)

Publication Number Publication Date
NO20011891D0 NO20011891D0 (no) 2001-04-17
NO20011891L true NO20011891L (no) 2001-07-02

Family

ID=26805566

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011891A NO20011891L (no) 1998-11-12 2001-04-17 Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon

Country Status (8)

Country Link
US (1) US6331408B1 (de)
EP (1) EP1129355B1 (de)
AT (1) ATE300052T1 (de)
AU (1) AU1618000A (de)
CA (1) CA2346099A1 (de)
DE (1) DE69926254D1 (de)
NO (1) NO20011891L (de)
WO (1) WO2000028331A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737038B1 (en) * 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
AU1618000A (en) * 1998-11-12 2000-05-29 Du Pont Pharmaceuticals Company Use of radioligands to screen inhibitors of amyloid-beta peptide production
EP1313426A2 (de) 1998-12-24 2003-05-28 Bristol-Myers Squibb Pharma Company Succinoylaminobenzodiazepine als inhibitoren der a-beta proteinproduktion
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
DE19909357A1 (de) * 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
US6525044B2 (en) 2000-02-17 2003-02-25 Bristol-Myers Squibb Company Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
CA2403550A1 (en) 2000-04-03 2001-10-11 Hong Liu Cyclic lactams as inhibitors of a-.beta. protein production
WO2001087354A2 (en) * 2000-05-17 2001-11-22 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
BR0106717A (pt) * 2000-06-01 2002-04-16 Bristol Myers Squibb Pharma Co Compostos, composição farmacêutica e usos dos compostos de lactama inovadora
WO2002086115A1 (en) * 2001-04-20 2002-10-31 The University Of Georgia Research Foundation, Inc. Active site inactivators
US20090062256A1 (en) * 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
CH698246B1 (de) * 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
CA2589860A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
EP2897938B1 (de) 2012-09-21 2017-03-15 Bristol-Myers Squibb Company Fluoralkyldibenzodiazepinonverbindungen
EP2897942B1 (de) 2012-09-21 2016-08-31 Bristol-Myers Squibb Company Fluoralkyl- und fluorocycloalkyl-1,4-benzodiazepinonverbindungen als notch-inhibitoren
JP2015533811A (ja) 2012-09-21 2015-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｎ−置換ビス（フルオロアルキル）１，４−ベンゾジアゼピノン化合物
JP2015534554A (ja) 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アルキル，フルオロアルキル−１，４−ベンゾジアゼピノン化合物
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
US9273075B2 (en) 2012-09-21 2016-03-01 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
EP2897944B1 (de) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Substituierte 1,5-benzodiazepinon-verbindungen
CN104822677A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
EP2897960B1 (de) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclische/heterocyclische verbindungen als notch-inhibitoren
EP2981267A1 (de) 2013-04-04 2016-02-10 Bristol-Myers Squibb Company Kombinationstherapie zur behandlung von proliferativen erkrankungen

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
US5252463A (en) * 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5538845A (en) * 1992-02-05 1996-07-23 Athena Neurosciences, Inc. Beta-amyloid peptide production inhibitors and methods for their identification
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5594006A (en) * 1993-03-18 1997-01-14 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
US5843941A (en) * 1993-05-14 1998-12-01 Genentech, Inc. Ras farnesyl transferase inhibitors
CZ184194A3 (en) * 1993-08-09 1995-03-15 Lilly Co Eli Aspartylprotease inhibitor and method of identifying thereof
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
AU6383396A (en) * 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
AU4589297A (en) * 1996-10-07 1998-05-05 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
US5734054A (en) * 1996-11-05 1998-03-31 Pharmacopeia, Inc. Hydroxy-amino acid amides
AU1618000A (en) * 1998-11-12 2000-05-29 Du Pont Pharmaceuticals Company Use of radioligands to screen inhibitors of amyloid-beta peptide production

Also Published As

Publication number Publication date
EP1129355A1 (de) 2001-09-05
ATE300052T1 (de) 2005-08-15
NO20011891D0 (no) 2001-04-17
CA2346099A1 (en) 2000-05-18
US6331408B1 (en) 2001-12-18
WO2000028331A1 (en) 2000-05-18
DE69926254D1 (de) 2005-08-25
AU1618000A (en) 2000-05-29
EP1129355B1 (de) 2005-07-20

Similar Documents

Publication Publication Date Title
NO20011891D0 (no) Anvendelse av radioligander for screening av inhibitorer av amyloid-&lt;beta&gt;-peptid produksjon
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
DE69432629D1 (de) Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
WO2003042654A3 (en) Multi-parameter high throughput screening assays (mphts)
WO2001087354A3 (en) Use of small molecule radioligands for diagnostic imaging
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
MXPA05003621A (es) Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
MY131442A (en) Excitatory amino acid receptor antagonists
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
TW200502221A (en) Novel lactams and uses thereof
EA200400699A1 (ru) 3,4-дизамещенные, 3,5-дизамещенные и 3,4,5-замещенные пиперидины и пиперазины
IL169889A0 (en) Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin
ATE522230T1 (de) Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
TR200200278T2 (tr) Kalsilitik bileşimler
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
WO2004005882A3 (en) Multi-parameter high throughput screening assays (mphts)
TW200504036A (en) Novel lactams and uses thereof
BR0314541A (pt) Tratamento de demência e doença de parkinson
WO2001049871A3 (en) Process for finding a protease inhibitor
WO2004047854A3 (en) Methods for the treatment of alzheimers disease and compositions therefore
WO1999006838A3 (en) Novel method of detecting amyloid-like fibrils or protein aggregates
ATE420637T1 (de) Verwendung von 1,2-diazadibenzoäe,hüazulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
WO2002048102A3 (fr) Isocoumarines inhibitrices de la production de peptide amyloide, preparation, compositions les contenant et utilisations
ATE372117T1 (de) Verwendung von 1,3-diazadibenzo(e,h) azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application